TREAT THE ITCH

associated with allergic conjunctivitis[1]

[Pr]BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% w/v is indicated for the treatment of itching associated with allergic conjunctivitis.

BEPREVE® demonstrated statistically significant reductions in ocular itching by 1.41 units on the ocular itch score after 3 minutes compared to placebo at visit 5 (onset of action) ($p<0.001$).†‡

BEPREVE® continued to significantly reduce ocular itch at the 8-hour visit (visit 4, 3 minutes post-CAC: 1.3-unit reduction in ocular itch score vs. placebo; $p<0.001$).†‡

Visit bepreve.ca to learn more

Clinical use:

- The safety and efficacy of BEPREVE® have not been established in pediatric patients under 3 years of age
- Efficacy of BEPREVE® in pediatric patients with age <10 was extrapolated from clinical trials conducted in pediatric patients with age >10 and in adults

Relevant warnings and precautions:

- For topical ophthalmic use only
- Do not touch the eyelids or surrounding areas with the dropper tip of the bottle and keep bottle tightly closed when not in use
- Do not use to treat contact lens-related irritation
- Do not instill while wearing contact lenses. Lenses may be reinserted after 10 minutes following administration.
- Should not be used in pregnant women unless the benefit to the mother justifies the potential risk to the fetus
- Caution when administered to nursing women

For more information:

Please consult the Product Monograph at http://www.bausch.ca/Portals/59/Files/Monograph/Pharma/bepreve-pm-en.pdf?ver=2016-10-03-132957-500 for important information relating to adverse reactions, drug interactions, and dosing information that has not been discussed in this piece.
The Product Monograph is also available by calling 1-800-361-4261.

† Efficacy was established in one Phase 2/3 and one Phase III, placebo-controlled, double-masked, randomized, conjunctival allergen challenge (CAC) clinical trial where participants were randomly assigned to BEPREVE® 1.5% w/v or placebo. CAC testing was done using multiple allergens, including both seasonal and perennial allergens. Study participants included males and females 10 years of age and older who had a positive history of allergic conjunctivitis. Ocular itching (measured on a 5-point scale, from 0 [none] to 4 [incapacitating itch with an irresistible urge to rub]) was evaluated at 3, 5 and 7 minutes following a CAC. Clinical significance was defined as change of more than one unit on the grading scale at a majority of timepoints evaluated.
‡ Visit 3B required 16 hours between investigational product dosing and CAC test. Visit 4 required 8 hours between investigational product dosing and CAC test. Visit 5 required 15 minutes between investigational product dosing and CAC test.

Reference: 1. BEPREVE® Product Monograph. Bausch + Lomb Incorporated. July 22, 2016.

BAUSCH+LOMB
Bausch + Lomb Canada, Vaughan, Ontario, L4K 4B4

110-3512E PAAB

Pr BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%